Safety and Effectiveness Study of The Swedish Adjustable Gastric Band (SAGB) in the Treatment of Morbid Obesity

Phase 3

Completed

Conditions: Obesity, Morbid

Interventions: Device: Swedish Adjustable Gastric Band

Registration Number: NCT00166205

Lead Sponsor: Ethicon Endo-Surgery

Brief Summary: The purpose of this study is to determine whether the Swedish Adjustable Gastric Band (SAGB) is safe, and effective in achieving weight loss in patients with Morbid Obesity.

Detailed Description: Surgical treatment of morbidly obese patients is considered a reasonable option for achieving weight loss when more conservative measures, such as diet and exercise have failed. Not only can weight loss be achieved, but also reduction / resolution of a patient's co-morbidities associated with excess weight. Adjustable gastric banding provides a less invasive, reversible bariatric surgery option. The SAGB has been commercially available outside the United States for this indication since 1996. Commercial availability has led to extensive literature supporting the safety and effectiveness of the SAGB. Given the available literature, a prospective, single arm, multicenter, study in a heterogeneous population of morbidly obese subjects in the U.S. is being conducted.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 276

Inclusion Criteria

Able to comprehend, follow and give signed informed consent;
18 to 60 years of age (inclusive);
Five year history of morbid obesity;
Body Mass Index (BMI) >40 kg/m2 and <55 kg/m2, or BMI >35 kg/m2 and <40 kg/m2 with one or more significant medical conditions related to obesity (co-morbid conditions of type 2 diabetes, hyperlipidemia, obstructive sleep apnea, hypertension, metabolic syndrome, or osteoarthritis of the hip or knee) for which the subject is being treated, and which are generally expected to be improved, reversed, or resolved by weight loss.
100 lbs. overweight or 1.5 times ideal weight;
Documented failure of conservative, non-surgical means of weight reduction within one year prior to the Screening Visit, including failure of supervised diet, exercise and or behavior modification programs, and pharmacologic therapy;
Willing to commit to significant lifestyle changes that include diet, eating, and exercise habits for the duration of the clinical trial;
Able to commit to long-term follow-up, including band adjustment visits:
Living within the contiguous U.S. and is within a 100 mile radius of the study center;
Absence of significant psychopathology that could limit the subject's ability to understand the procedure, comply with medical, surgical, and/or behavioral recommendations, as documented during screening assessment;
Agrees to refrain from any type of reconstructive surgery that would affect body weight such as abdominal lipoplasty or liposuction, mammoplasty, or removal of excess skin for the follow-up period following SAGB placement; and
Candidate for surgical weight loss intervention (i.e., meets accepted health criteria for major surgery).

Exclusion Criteria

Women of childbearing potential who are not practicing an effective method of birth control or who are pregnant or lactating;
Previous malabsorptive or restrictive procedures performed for the treatment of obesity;
Documented history of drug and/or alcohol abuse within two years of the Screening Visit;
History of impaired mental status including, but not limited to active substance abuse, a history of schizophrenia, borderline personality disorder, uncontrolled depression, suicidal attempts within the past two years or current suicidal tendencies or ideations;
Presence of any of the following medical conditions;
- Inflammatory diseases of the gastrointestinal tract, including severe intractable esophagitis, gastric ulceration, duodenal ulceration, or specific inflammation such as Crohn's disease that have been active within the past 10 years;
- Congenital or acquired anomalies of the GI tract, including atresias or stenosis,
- Severe cardiopulmonary disease or other serious organic disease that makes the subject a high-risk surgical candidate;
- Uncontrolled hypertension;
- Portal Hypertension;
- Uncontrolled Diabetes Mellitus;
- Chronic or acute upper gastrointestinal bleeding conditions, e.g. gastric or esophageal varices;
- Cirrhosis;
- Congenital or acquired intestinal telangiectasia;
- Esophageal or gastric disorders including severe preoperative reflux, dysmotility, or Barrett's Esophagus;
- Presence of hiatal hernia;
- Prior surgery of the foregut including hiatal hernia repair or prior gastric surgery;
- Chronic pancreatitis;
- Immunocompromised such as that resulting from chronic oral steroid use, chemotherapeutic agents, or immune deficiency disorders;
- Conditions that, in the opinion of the investigator, may jeopardize the subject's well-being and/or the soundness of this clinical study;
History or presence of pre-existing autoimmune connective tissue disease, i.e., systemic lupus erythematosus or scleroderma;
Presence of terminal illness with life expectancy <5 years;
Use of prescription or over the counter weight reduction medications or supplements within one month of the Screening Visit and for the duration of study participation;
Acute or chronic infection (localized or systemic);
Known or suspected allergy to silicone or other materials contained in the Swedish Adjustable Gastric Band;
History of intolerance to implanted devices;
Not ambulatory; and
Participation in another clinical trial within 8 weeks of the Screening Visit and for the duration of this trial.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Gastric Band	Swedish Adjustable Gastric Band	Single-arm study, all subjects banded.

Primary Outcome Measures

Name	Time	Method
Percent of Subjects Who Had Adverse Events With the Swedish Adjustable Gastric Band (SAGB)	3 years	Percent of device-related adverse events (AEs) and device malfunctions occurring in subjects implanted with the Swedish Adjustable Gastric Band from baseline throughout the three-year post-operative period.
Percent Excess Weight Loss	3 Years Post Operative	Percent Excess Weight Loss (%EWL) with the SAGB at three years post operatively minus baseline.

Secondary Outcome Measures

Name	Time	Method
Changes in Quality of Life (QOL) Measures	3 years	Changes in QOL measures at three-years post-operative minus baseline. SF-36 scores from 0-100 with higher scores representing better QOL.
Changes in Glycosylated Hemoglobin (HbA1c)	3 years	Changes in glycosylated hemoglobin (HbA1c), from baseline to three-years post-operative.
Changes in Body Mass Index (BMI)	3 years	Changes in Body Mass Index (BMI) at three-years post-operative minus baseline.
Change in Absolute Weight	3 years	Absolute weight loss as measured on a standardized Tanita Scale (used at all sites) at three-years post-operative minus baseline.
Changes in Low Density Lipoproteins (LDL)	3 years	Changes in Low Density Lipoproteins (LDL), at three-years post-operative minus baseline.
Changes in Excess Body Weight (EBW)	3 years	Changes in excess body weight at 3-years post-operative minus baseline excess weight. Excess weight is computed as baseline weight minus Ideal weight. Ideal weight as provided in the 1983 Metropolitan Life Height and Weight Table using the upper limit of the midpoint range.
Changes in Total Cholesterol	3 years	Changes in Total Cholesterol, at three-years post-operative minus baseline.
Number of All Adverse Events of Subjects Implanted With the SAGB	3 Years	The evaluation of all Adverse Events of subjects implanted with the Swedish Adjustable Gastric Band throughout the three-year post-operative period (related to device and unrelated to device).
Changes in High Density Lipoproteins (HDL)	3 year	Changes in High Density Lipoproteins (HDL), at three-years post-operative minus baseline.

Trial Locations

Locations (12): US Bariatrics
🇺🇸
Ft. Lauderdale, Florida, United States
University of Minnesota
🇺🇸
Minneapolis, Minnesota, United States
Cedars-Sinai Medical Center
🇺🇸
Los Angeles, California, United States
Advanced Surgical Institute at Mercy Hospital
🇺🇸
Miami, Florida, United States
Scripps Clinic Medical Group
🇺🇸
San Diego, California, United States
Hamilton Medical Center - Weight Management
🇺🇸
Dalton, Georgia, United States
Cleveland Clinic Florida
🇺🇸
Weston, Florida, United States
Weight Management Center
🇺🇸
New Orleans, Louisiana, United States
Dartmouth-Hitchcock Medical Center
🇺🇸
Lebanon, New Hampshire, United States
CAREMAX Surgical, P.C.
🇺🇸
East Patchogue, New York, United States
St. Luke's-Roosevelt Hospital Center
🇺🇸
New York, New York, United States
Surgical Consultants of San Antonio
🇺🇸
San Antonio, Texas, United States